Concentric Analgesics Raises $76 Million in Series B Financing
May 21, 2019 16:03 ET
|
Concentric Analgesics, Inc.
Proceeds will advance development of CA-008, a potential first-in-class long-lasting non-opioid therapeutic for the treatment of post-surgical pain Raise also supports continued development of...
Concentric Analgesics to Present at the Cowen 39th Annual Healthcare Conference
March 04, 2019 08:00 ET
|
Concentric Analgesics, Inc.
SAN FRANCISCO, March 04, 2019 (GLOBE NEWSWIRE) -- Concentric Analgesics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel, non-opioid pain...
Concentric Analgesics Announces Positive Topline Results from Phase 2 Clinical Trial of CA-008 in Bunionectomy
November 08, 2018 08:00 ET
|
Concentric Analgesics, Inc.
Clinically Meaningful Reductions in Pain Lasting Through One Week vs. Active Control 50% Reduction in Opioid Use with 26% of Patients Opioid Free For 28 Days SAN FRANCISCO, Nov. 08, 2018 (GLOBE...